Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
<sup>177</sup>Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease the ability of tumour cells...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/11/1570 |
| _version_ | 1797511160220614656 |
|---|---|
| author | Andreas Hallqvist Johanna Svensson Linn Hagmarker Ida Marin Tobias Rydén Jean-Mathieu Beauregard Peter Bernhardt |
| author_facet | Andreas Hallqvist Johanna Svensson Linn Hagmarker Ida Marin Tobias Rydén Jean-Mathieu Beauregard Peter Bernhardt |
| author_sort | Andreas Hallqvist |
| collection | DOAJ |
| description | <sup>177</sup>Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease the ability of tumour cells to repair <sup>177</sup>Lu-induced DNA damage. To decrease the risk of side effects, the sequencing should be optimized according to the tumour-to-normal tissue enhanced dose ratio (<i>TNED</i>). The aim of this study was to investigate how to enhance <sup>177</sup>Lu-DOTATATE by optimal timing of the addition of a PARP inhibitor. Biokinetic modelling was performed based on the absorbed dose to the bone marrow, kidneys and tumour; determined from SPECT/CT and planar images from 17 patients treated with <sup>177</sup>Lu-DOTATATE. To investigate the theoretical enhanced biological effect of a PARP inhibitor during <sup>177</sup>Lu-DOTATATE treatment, the concept of relative biological effectiveness (<i>RBE</i>) was used, and PARP inhibitor administration was simulated over different time intervals. The absorbed dose rate for the tumour tissue demonstrated an initial increase phase until 12 h after infusion followed by a slow decrease. In contrast, the bone marrow showed a rapid initial dose rate decrease. Twenty-eight days after infusion of <sup>177</sup>Lu-DOTATATE, the full absorbed dose to the bone marrow and kidney was reached. Using an <i>RBE</i> value of 2 for both the tumour and normal tissues, the <i>TNED</i> was increased compared to <sup>177</sup>Lu-DOTATATE alone. According to the modelling, the PARP inhibitor should be introduced approximately 24 h after the start of <sup>177</sup>Lu-DOTATATE treatment and be continued for up to four weeks to optimize the <i>TNED</i>. Based on these results, a phase I trial assessing the combination of olaparib and <sup>177</sup>Lu-DOTATATE in somatostatin receptor-positive tumours was launched in 2020 (NCT04375267). |
| first_indexed | 2024-03-10T05:41:30Z |
| format | Article |
| id | doaj.art-a9754249b27b4e299cd42ae821706fd7 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T05:41:30Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-a9754249b27b4e299cd42ae821706fd72023-11-22T22:30:08ZengMDPI AGBiomedicines2227-90592021-10-01911157010.3390/biomedicines9111570Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry RationaleAndreas Hallqvist0Johanna Svensson1Linn Hagmarker2Ida Marin3Tobias Rydén4Jean-Mathieu Beauregard5Peter Bernhardt6Department of Oncology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 41345 Gothenburg, SwedenDepartment of Oncology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 41345 Gothenburg, SwedenMedical Physics and Biomedical Engineering, Sahlgrenska University Hospital, 43415 Gothenburg, SwedenDepartment of Medical Radiation Sciences, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 43415 Gothenburg, SwedenDepartment of Medical Radiation Sciences, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, 43415 Gothenburg, SwedenDepartment of Medical Imaging, CHU de Québec-Université Laval, Quebec City, QC G1R 3S1, CanadaMedical Physics and Biomedical Engineering, Sahlgrenska University Hospital, 43415 Gothenburg, Sweden<sup>177</sup>Lu-DOTATATE for neuroendocrine tumours is considered a low-toxicity treatment and may therefore be combined with other pharmaceuticals to potentiate its efficacy. One approach is to add a poly-[ADP-ribose]-polymerase (PARP) inhibitor to decrease the ability of tumour cells to repair <sup>177</sup>Lu-induced DNA damage. To decrease the risk of side effects, the sequencing should be optimized according to the tumour-to-normal tissue enhanced dose ratio (<i>TNED</i>). The aim of this study was to investigate how to enhance <sup>177</sup>Lu-DOTATATE by optimal timing of the addition of a PARP inhibitor. Biokinetic modelling was performed based on the absorbed dose to the bone marrow, kidneys and tumour; determined from SPECT/CT and planar images from 17 patients treated with <sup>177</sup>Lu-DOTATATE. To investigate the theoretical enhanced biological effect of a PARP inhibitor during <sup>177</sup>Lu-DOTATATE treatment, the concept of relative biological effectiveness (<i>RBE</i>) was used, and PARP inhibitor administration was simulated over different time intervals. The absorbed dose rate for the tumour tissue demonstrated an initial increase phase until 12 h after infusion followed by a slow decrease. In contrast, the bone marrow showed a rapid initial dose rate decrease. Twenty-eight days after infusion of <sup>177</sup>Lu-DOTATATE, the full absorbed dose to the bone marrow and kidney was reached. Using an <i>RBE</i> value of 2 for both the tumour and normal tissues, the <i>TNED</i> was increased compared to <sup>177</sup>Lu-DOTATATE alone. According to the modelling, the PARP inhibitor should be introduced approximately 24 h after the start of <sup>177</sup>Lu-DOTATATE treatment and be continued for up to four weeks to optimize the <i>TNED</i>. Based on these results, a phase I trial assessing the combination of olaparib and <sup>177</sup>Lu-DOTATATE in somatostatin receptor-positive tumours was launched in 2020 (NCT04375267).https://www.mdpi.com/2227-9059/9/11/1570<sup>177</sup>Lu-DOTATATEPARP inhibitorsomatostatin positive tumorolaparib |
| spellingShingle | Andreas Hallqvist Johanna Svensson Linn Hagmarker Ida Marin Tobias Rydén Jean-Mathieu Beauregard Peter Bernhardt Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale Biomedicines <sup>177</sup>Lu-DOTATATE PARP inhibitor somatostatin positive tumor olaparib |
| title | Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale |
| title_full | Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale |
| title_fullStr | Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale |
| title_full_unstemmed | Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale |
| title_short | Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale |
| title_sort | optimizing the schedule of parp inhibitors in combination with sup 177 sup lu dotatate a dosimetry rationale |
| topic | <sup>177</sup>Lu-DOTATATE PARP inhibitor somatostatin positive tumor olaparib |
| url | https://www.mdpi.com/2227-9059/9/11/1570 |
| work_keys_str_mv | AT andreashallqvist optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale AT johannasvensson optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale AT linnhagmarker optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale AT idamarin optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale AT tobiasryden optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale AT jeanmathieubeauregard optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale AT peterbernhardt optimizingthescheduleofparpinhibitorsincombinationwithsup177supludotatateadosimetryrationale |